European Journal of Clinical Pharmacology

, Volume 75, Issue 2, pp 189–194 | Cite as

Response to sertraline is influenced by GNβ3 gene G-350A variant in patients with major depressive disorder

  • Dena Firouzabadi
  • Negar FirouzabadiEmail author
  • Kiana Kalani
  • Kamyar Zomorrodian
  • Elham Shirazi Tehrani



Heterotrimeric guanine nucleotide-binding proteins (G proteins) are a major group of human genome membrane protein receptors. Genetic variation in the β3 subunit (GNβ3) associated with gene splicing and increased activity is associated with major depressive disorder (MDD). However, the effect of G-350A GNβ3 genetic polymorphism and therapeutic outcome of selective serotonin reuptake inhibitors (SSRIs) in MDD has not yet been studied.


One hundred newly diagnosed MDD patients were treated with sertraline for 6 weeks. The severity of depressive symptoms was weekly assessed by Hamilton Rating Scale for Depression (HRSD). A 50% decrease in HRSD was defined as response to treatment. GNβ3 polymorphisms (G-350A, A657T) were determined in each individual using a PCR-RFLP technique.


Our results suggested that subjects with GG genotype of G-350A responded 5.9-folds more to sertraline compared to carriers of other variants (P = 0.004, OR = 5.9; 95% CI = 1.66–21.99). In addition, carriers of the G allele responded 1.9-folds more to sertraline than carriers of the A allele (P = 0.032, OR = 1.92; 95% CI = 1.05–3.65). However, no association was observed between A657T variants and response to sertraline (P = 0.920, OR = 0.9; 95% CI = 0.31–2.69).


The results suggest that G-350A variant of GNβ3 plays a foremost part as a predictor of response to antidepressant treatment.


Pharmacogenetics Polymorphism Sertraline Depression 



This manuscript is dedicated to Professor Habib Firouzabadi, on the occasion of his 75th birthday.

Contributions of authors

Negar Firouzabadi: Design of the work, analysis, and interpretation of data for the work, drafting the work, and final approval of the manuscript.

Dena Firouzabadi: Analysis and interpretation of data for the work, revising the manuscript critically for important intellectual content, and final approval of the manuscript.

Kiana Kalani: Substantial contributions to the conception of the project, drafting the manuscript, and final approval of the manuscript.

Kamiar Zomorodian: Design of the work, analysis, and interpretation of data for the work, drafting the work, and final approval of the manuscript.

Elham Shirazi Tehrani: Analysis and interpretation of data for the work, revising the manuscript critically for important intellectual content, and final approval of the manuscript.

Compliance with ethical standards

This study was approved by the local committee for ethics of medical experiments on human subjects of Shiraz University of Medical Sciences and carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and Uniform Requirements for manuscripts submitted to biomedical journals.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Ray RS, Corcoran AE, Brust RD, Kim JC, Richerson GB, Nattie E, Dymecki SM (2011) Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition. Science 333(6042):637–642CrossRefGoogle Scholar
  2. 2.
    Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Annu Rev Med 60:355–366CrossRefGoogle Scholar
  3. 3.
    Meltzer HY, Roth BL (2013) Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs. J Clin Invest 123(12):4986–4991CrossRefGoogle Scholar
  4. 4.
    Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C (1989) A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatr Scand 80(S350):117–123CrossRefGoogle Scholar
  5. 5.
    Laws D, Ashford J, Anstee J (1990) A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 81(2):185–189CrossRefGoogle Scholar
  6. 6.
    Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I (1998) Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. Jama 280(8):708–713CrossRefGoogle Scholar
  7. 7.
    Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS (1989) Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 46(1):36–44CrossRefGoogle Scholar
  8. 8.
    van der Kolk B, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G (1994) Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 5(12):517–522Google Scholar
  9. 9.
    Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L (1997) Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95(5):444–450CrossRefGoogle Scholar
  10. 10.
    Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D, Campeas R, Liebowitz MR (1998) An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol 18(1):10–18CrossRefGoogle Scholar
  11. 11.
    Nutt DJ, Forshall S, Bell C, Rich A, Sandford J, Nash J, Argyropoulos S (1999) Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 9:S81–S86CrossRefGoogle Scholar
  12. 12.
    Gray JA, Roth BL (2001) Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists. Brain Res Bull 56(5):441–451CrossRefGoogle Scholar
  13. 13.
    Armbruster BN, Roth BL (2005) Mining the receptorome. J Biol Chem 280(7):5129–5132CrossRefGoogle Scholar
  14. 14.
    Birnbaumer L, Abramowitz J, Brown AM (1990) Receptor-effector coupling by G proteins. Biochim Biophys Acta Rev Biomembr 1031(2):163–224CrossRefGoogle Scholar
  15. 15.
    Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56(1):615–649CrossRefGoogle Scholar
  16. 16.
    Drazen JM, Silverman EK, Lee TH (2000) Heterogeneity of therapeutic responses in asthma. Br Med Bull 56(4):1054–1070CrossRefGoogle Scholar
  17. 17.
    Zill P, Baghai TC, Zwanzger P, Schüle C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B (2000) Evidence for an association between a G-protein β3-gene variant with depression and response to antidepressant treatment. Neuroreport 11(9):1893–1897CrossRefGoogle Scholar
  18. 18.
    Pinsonneault J, Sadée W (2003) Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome. AAPS PharmSci 5(4):49–61CrossRefGoogle Scholar
  19. 19.
    MacQueen G, Born L, Steiner M (2001) The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev 7(1):1–24CrossRefGoogle Scholar
  20. 20.
    Richelson E (1994) Pharmacology of antidepressants—characteristics of the ideal drug. In: Mayo Clinic Proceedings ed. Elsevier, pp 1069–1081Google Scholar
  21. 21.
    Firouzabadi N, Raeesi R, Zomorrodian K, Bahramali E, Yavarian I (2017) Beta adrenoceptor polymorphism and clinical response to sertraline in major depressive patients. J Pharm Pharm Sci 20:1–7CrossRefGoogle Scholar
  22. 22.
    Serretti A, Franchini L, Gasperini M, Rampoldi R, Smeraldi E (1998) Mode of inheritance in mood disorder families according to fluvoxamine response. Acta Psychiatr Scand 98(6):443–450CrossRefGoogle Scholar
  23. 23.
    Miller S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefGoogle Scholar
  24. 24.
    Rosskopf D, Busch S, Manthey I, Siffert W (2000) G protein β3 gene: structure, promoter, and additional polymorphisms. Hypertension 36(1):33–41CrossRefGoogle Scholar
  25. 25.
    Machado M, Iskedjian M, Ruiz I, Einarson TR (2006) Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 22(9):1825–1837CrossRefGoogle Scholar
  26. 26.
    Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatr 163(1):28–40CrossRefGoogle Scholar
  27. 27.
    Franchini L, Serretti A, Gasperini M, Smeraldi E (1998) Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 32(5):255–259CrossRefGoogle Scholar
  28. 28.
    Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, Brockmöller J (2008) Genetic variants in FKBP5 affecting response to antidepressant drug treatment Future Medicine 9(7):1––7Google Scholar
  29. 29.
    Maier W, Zobel A (2008) Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci 258(1):12–20CrossRefGoogle Scholar
  30. 30.
    Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA (2003) Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein β 3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 6(4):339–346CrossRefGoogle Scholar
  31. 31.
    Serretti A, Lorenzi C, Cusin C, Zanardi R, Lattuada E, Rossini D, Lilli R, Pirovano A, Catalano M, Smeraldi E (2003) SSRIs antidepressant activity is influenced by Gβ3 variants. Eur Neuropsychopharmacol 13(2):117–122CrossRefGoogle Scholar
  32. 32.
    Klenke S, Kussmann M, Siffert W (2011) The GNB3 C825T polymorphism as a pharmacogenetic marker in the treatment of hypertension, obesity, and depression. Pharmacogenet Genomics 21(9):594–606CrossRefGoogle Scholar
  33. 33.
    Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT (1999) G protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders. J Neurochem 73(3):1121–1126CrossRefGoogle Scholar
  34. 34.
    Young LT, Li PP, Kamble A, Siu KP, Warsh JJ (1994) Mononuclear leukocyte levels of G proteins in depressed patients with bipolar disorder or major depressive disorder. Am J Psychiatry 151(4):594–596CrossRefGoogle Scholar
  35. 35.
    Avissar S, Barki-Harrington L, Nechamkin Y, Roitman G, Schreiber G (1996) Reduced β-adrenergic receptor-coupled Gs protein function and Gsα immunoreactivity in mononuclear leukocytes of patients with depression. Biol Psychiatry 39(9):755–760CrossRefGoogle Scholar
  36. 36.
    Bousman CA, Potiriadis M, Everall IP, Gunn JM (2014) G-protein β3 subunit genetic variation moderates five-year depressive symptom trajectories of primary care attendees. J Affect Disord 165:64–68CrossRefGoogle Scholar
  37. 37.
    Müller DJ, De Luca V, Sicard T, King N, Hwang R, Volavka J, Czobor P, Sheitman BB, Lindenmayer J-P, Citrome L (2005) Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 15(5):525–531CrossRefGoogle Scholar
  38. 38.
    Kato M, Wakeno M, Okugawa G, Fukuda T, Takekita Y, Hosoi Y, Azuma J, Kinoshita T, Serretti A (2008) Antidepressant response and intolerance to SSRI is not influenced by G-protein β3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog Neuro-Psychopharmacol Biol Psychiatry 32(4):1041–1044CrossRefGoogle Scholar
  39. 39.
    Willeit M, Praschak-Rieder N, Zill P, Neumeister A, Ackenheil M, Kasper S, Bondy B (2003) C825T polymorphism in the G protein β3-subunit gene is associated with seasonal affective disorder. Biol Psychiatry 54(7):682–686CrossRefGoogle Scholar
  40. 40.
    Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann H-E, Jakobs KH (1998) Association of a human G-protein β3 subunit variant with hypertension. Nat Genet 18(1):45–48CrossRefGoogle Scholar
  41. 41.
    Hirschfeld RM (1999) Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 60(5):326–335CrossRefGoogle Scholar
  42. 42.
    Suri RA, Altshuler LL, Rasgon NL, Calcagno JL, Frye MA, Gitlin MJ, Hwang S, Zuckerbrow-Miller J (2000) Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 61(12):942–946CrossRefGoogle Scholar
  43. 43.
    Ozomaro U, Wahlestedt C, Nemeroff CB (2013) Personalized medicine in psychiatry: problems and promises. BMC Med 11(1):132CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Dena Firouzabadi
    • 1
  • Negar Firouzabadi
    • 2
    Email author
  • Kiana Kalani
    • 2
  • Kamyar Zomorrodian
    • 3
    • 4
  • Elham Shirazi Tehrani
    • 2
  1. 1.Department of Clinical Pharmacy, School of PharmacyShiraz University of Medical SciencesShirazIran
  2. 2.Department of Pharmacology and Toxicology, School of PharmacyShiraz University of Medical SciencesShirazIran
  3. 3.Basic Sciences in Infectious Diseases Research CenterShirazIran
  4. 4.Department of Medical Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran

Personalised recommendations